FEMY
Femasys Inc

3,138
Loading...
Loading...
News
all
press releases
Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates
Femasys (FEMY) delivered earnings and revenue surprises of +11.11% and -48.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -2,266.67% and -99.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates
Vir Biotechnology (VIR) delivered earnings and revenue surprises of -11.11% and -84.12%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Femasys Stock Slides After Company Prices Public Offering At Discount: Retail’s Planning To Load Up
The offer price of $0.85 represents a discount of about 17% from the stock’s closing price on Thursday.
Stocktwits·4mo ago
News Placeholder
Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates
chainwire·4mo ago
News Placeholder
Femasys Reports Wider-Than-Expected Annual Loss, But Retail Continues To Be Optimistic
The company said that as of the end of 2024, it had an accumulated deficit of $127.2 million and cash and cash equivalents of only $3.5 million.
Stocktwits·6mo ago
News Placeholder
EXCLUSIVE: Femasys At Inflection Point And Undervalued, Expects Growth Potential Following Roe v. Wade Overturn, CEO Says
Femasys focuses on innovative women's healthcare solutions. Their FemBloc product, a non-surgical permanent birth control, is in late-stage development, aiming for a $20 billion market. read more...
Benzinga·1y ago
News Placeholder
Femasys: A Buy Rating on Innovative Reproductive Solutions and Market Expansion Potential
Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Femasys (FEMY Research Report). The associated price target remains the...
TipRanks Financial Blog·1y ago
News Placeholder
Femasys price target raised by $2 at H.C. Wainwright, here's why
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·1y ago
News Placeholder
Femasys (NASDAQ:FEMY) Posts Quarterly Earnings Results, Hits Expectations
Femasys (NASDAQ:FEMY - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.19) earnings per share for the quarter, meeting the consensus estimate of...
Ticker Report·1y ago

Latest FEMY News

View

Advertisement. Remove ads.

Advertisement. Remove ads.